An evaluation of early medication use for COPD: a population-based cohort study

被引:12
作者
Falk, Jamie [1 ]
Dik, Natalia [2 ]
Bugden, Shawn [1 ]
机构
[1] Univ Manitoba, Coll Pharm, Rady Fac Hlth Sci, Winnipeg, MB, Canada
[2] Univ Manitoba, Manitoba Ctr Hlth Policy, Dept Community Hlth Sci, Winnipeg, MB, Canada
来源
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE | 2016年 / 11卷
关键词
COPD; medication; inhaled steroids; Canada; guideline; appropriate; OBSTRUCTIVE PULMONARY-DISEASE; MANAGEMENT; EFFICACY; PATTERNS; SAFETY; CARE;
D O I
10.2147/COPD.S123643
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Purpose: The aim of this study was to evaluate the first initiation, sequence of addition, and appropriate prescribing of COPD medications in Manitoba, Canada. Patients and methods: A population-based cohort study of COPD medication use was conducted using administrative health care data (1997-2012). Those aged >= 35 years with COPD based on three or more COPD-related outpatient visits over a rolling 24-month window or at least one COPD-related hospitalization were included. The first medication(s) dispensed on or after the date of COPD diagnosis were determined based on pharmacy claims. The next medication(s) in sequence were determined to be additions or switches to the previous regimen. Evaluation of guideline-based appropriateness to receive inhaled corticosteroids (ICS) was based on exacerbation history and past medication use. Results: Of 13,369 patients dispensed COPD medications after diagnosis, 66.0% were dispensed short-acting bronchodilators as first medications. Although long-acting bronchodilators alone were uncommonly used as first or subsequent medications, ICS were dispensed as first medications in 28.2% of patients. Over the study period, use of short-acting bronchodilators as first medications declined from 70.6% to 59.4% (P< 0.0001), whereas the use of ICS as a first medication increased from 23.5% to 34.4% (P< 0.0001). Dispensation of an ICS plus a long-acting beta-agonist increased dramatically from 1.2% to 27.3% (P< 0.0001). By the end of the study period, the majority of patients (53.3%) were being initiated on two or more medications. Of 5,823 patients dispensed an ICS, 52.4% met Canadian guideline criteria for initiating an ICS, whereas 0.3% met Global Initiative for Chronic Obstructive Lung Disease guideline criteria. Conclusion: The use of first-line medications has declined over time, replaced primarily by combination inhalers prescribed early without prior trials of appropriate next step medications. This, along with an increasingly predominant use of multiple first medications, indicates a significant degree of medication burden in this already complex patient population.
引用
收藏
页码:3101 / 3108
页数:8
相关论文
共 27 条
[1]  
[Anonymous], 2015, Global Strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease
[2]   Dual bronchodilation with QVA149 versus single bronchoditator therapy: the SHINE study [J].
Bateman, Eric D. ;
Ferguson, Gary T. ;
Barnes, Neil ;
Gallagher, Nicola ;
Green, Yulia ;
Henley, Michelle ;
Banerji, Donald .
EUROPEAN RESPIRATORY JOURNAL, 2013, 42 (06) :1484-1494
[3]   Practice patterns in the management of chronic obstructive pulmonary disease in primary practice: The CAGE study [J].
Bourbeau, Jean ;
Sebaldt, Rolf J. ;
Day, Anna ;
Bouchard, Jacques ;
Kaplan, Alan ;
Hernandez, Paul ;
Rouleau, Michel ;
Petrie, Annie ;
Foster, Gary ;
Thabane, Lehana ;
Haddon, Jennifer ;
Scalera, Alissa .
CANADIAN RESPIRATORY JOURNAL, 2008, 15 (01) :13-19
[4]   Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease [J].
Calverley, Peter M. A. ;
Anderson, Julie A. ;
Celli, Bartolome ;
Ferguson, Gary T. ;
Jenkins, Christine ;
Jones, Paul W. ;
Yates, Julie C. ;
Vestbo, Jorgen ;
Calverley, P. M. A. ;
Anderson, J. A. ;
Celli, B. ;
Ferguson, G. T. ;
Jenkins, C. ;
Jones, P. W. ;
Knobil, K. ;
Yates, J. C. ;
Vestbo, J. ;
Cherniack, R. ;
Similowski, T. ;
Cleland, J. ;
Whitehead, A. ;
Wise, R. ;
McGarvey, L. ;
John, M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (08) :775-789
[5]   Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease [J].
Cheyne, Leanne ;
Irvin-Sellers, Melanie J. ;
White, John .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (09)
[6]   Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials [J].
Decramer, Marc ;
Anzueto, Antonio ;
Kerwin, Edward ;
Kaelin, Thomas ;
Richard, Nathalie ;
Crater, Glenn ;
Tabberer, Maggie ;
Harris, Stephanie ;
Church, Alison .
LANCET RESPIRATORY MEDICINE, 2014, 2 (06) :472-486
[7]  
Falk J., 2015, PHARM PRACT PLUS, V2, P26
[8]   Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease [J].
Farne, Hugo A. ;
Cates, Christopher J. .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2015, (10)
[9]   Prescription Practices for Chronic Obstructive Pulmonary Disease: Findings from the National Ambulatory Medical Care Survey 1999-2010 [J].
Ford, Earl S. ;
Mannino, David M. ;
Giles, Wayne H. ;
Wheaton, Anne G. ;
Liu, Yong ;
Croft, Janet B. .
COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2014, 11 (03) :247-255
[10]   Comorbidity in patients with chronic obstructive pulmonary disease in family practice: a cross sectional study [J].
Garcia-Olmos, Luis ;
Alberquilla, Angel ;
Ayala, Victoria ;
Garcia-Sagredo, Pilar ;
Morales, Leticia ;
Carmona, Montserrat ;
de Tena-Davila, Maria Jose ;
Pascual, Mario ;
Munoz, Adolfo ;
Salvador, Carlos H. ;
Monteagudo, Jose L. .
BMC FAMILY PRACTICE, 2013, 14